Ethan Phillip M. LaRochelle

Ethan Phillip M. LaRochelle

Auto-generated profile, based on publicly available information

Ethan Phillip M. LaRochelle

QUEL Imaging, White River Junction, Vermont, United States

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Journal of Critical Care
Verified
Journal Article
Closed access
MMMichael J. Massey
Michael J. Massey
ELEthan LaRochelle
Ethan LaRochelle
GNGabriel Najarro
Gabriel Najarro
AKAdarsh Karmacharla
Adarsh Karmacharla
RARyan Arnold
Ryan Arnold
NSNathan I. Shapiro
Nathan I. Shapiro

13 April 2018 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
BPBrian W. Pogue
Brian W. Pogue
JFJinchao Feng
Jinchao Feng
ELEthan P. LaRochelle
Ethan P. LaRochelle
PBPetr Bruža
Petr Bruža
HLHuiyun Lin
Huiyun Lin
LJLesley A. Jarvis
Lesley A. Jarvis

29 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
XCXu Cao
Xu Cao
SASrinivasa Rao Allu
Srinivasa Rao Allu
SJShudong Jiang
Shudong Jiang
MJMengyu Jia
Mengyu Jia
JGJason R. Gunn
Jason R. Gunn
BPBrian W. Pogue
Brian W. Pogue
Hypoxia in solid tumors is thought to be an important factor in resistance to therapy, but the extreme microscopic heterogeneity of the partial pressures of oxygen (pO2) between the capillaries makes it difficult to characterize the scope of this phenomenon without invasive sampling of oxygen distributions throughout the tissue. Here we develop a non-invasive method to track spatial oxygen distributions in tumors during fractionated radiotherapy, using oxygen-dependent quenching of phosphorescence, oxygen probe Oxyphor PtG4 and the radiotherapy-induced Cherenkov light to excite and image the phosphorescence lifetimes within the tissue. Mice bearing MDA-MB-231 breast cancer and FaDu head neck cancer xenografts show different pO2 responses during each of the 5 fractions (5 Gy per fraction), delivered from a clinical linear accelerator. This study demonstrates subsurface in vivo mapping of tumor pO2 distributions with submillimeter spatial resolution, thus providing a methodology to track response of tumors to fractionated radiotherapy.

21 May 2020 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
ARAlberto J. Ruiz
Alberto J. Ruiz
MWMindy Wu
Mindy Wu
ELEthan Philip M. LaRochelle
Ethan Philip M. LaRochelle
DGDimitris Gorpas
Dimitris Gorpas
VNVasilis Ntziachristos
Vasilis Ntziachristos
BPBrian W. Pogue
Brian W. Pogue
Fluorescence imaging in surgery allows for visualization of biologically relevant markers that are indicated to guide rapid decision-making during the procedure.1 – 3 The use of fluorescence-guided surgery (FGS) has been growing at a steady pace over the past 70 years, with rapid expansion over the last decade as the imaging technologies have matured to enable seamless integration into the clinical workflow.2 Indocyanine green (ICG) is by far the most widely used tissue perfusion agent and cardiac flow indicator within FGS.4 The success of ICG within fluorescence imaging can be attributed to its absorption and emission in the near-infrared (NIR) range, its low toxicity, and its history of use within medicine for over half a century.2,4 – 6 As the field of FGS expands, there is a wider range of imaging systems that are indicated for the same uses, such that there is a compelling need for standards that enable system characterization, performance monitoring, and intersystem comparisons or calibration.7 – 10 The performance of imaging systems can affect surgical decision making,7 so knowledge of their performance capabilities is especially relevant given the real-time decisions that are made with these systems during surgical procedures.

1 January 2018 in Cancer Control
Verified
Journal Article
Open access
KSKimberley S. Samkoe
Kimberley S. Samkoe
BBBrent D. Bates
Brent D. Bates
JEJonathan T. Elliott
Jonathan T. Elliott
ELEthan LaRochelle
Ethan LaRochelle
JGJason R. Gunn
Jason R. Gunn
EHEric R. Henderson
Eric R. Henderson
The excision of tumors by wide local excision is challenging because the mass must be removed entirely without ever viewing it directly. Positive margin rates in sarcoma resection remain in the range of 20% to 35% and are associated with increased recurrence and decreased survival. Fluorescence-guided surgery (FGS) may improve surgical accuracy and has been utilized in other surgical specialties. ABY-029, an anti-epidermal growth factor receptor Affibody molecule covalently bound to the near-infrared fluorophore IRDye 800CW, is an excellent candidate for future FGS applications in sarcoma resection; however, conventional methods with direct surface tumor visualization are not immediately applicable. A novel technique involving imaging through a margin of normal tissue is needed. We review the past and present applications of FGS and present a novel concept of indirect FGS for visualizing tumor through a margin of normal tissue and aiding in excising the entire lesion as a single, complete mass with tumor-free margins.

1 March 2019 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
ELEthan P.M. LaRochelle
Ethan P.M. LaRochelle
KMKayla Marra
Kayla Marra
RLRobert E. LeBlanc
Robert E. LeBlanc
MCM. Shane Chapman
M. Shane Chapman
EMEdward V. Maytin
Edward V. Maytin
BPBrian W. Pogue
Brian W. Pogue